Last reviewed · How we verify

ADASUVE® — Competitive Intelligence Brief

ADASUVE® (ADASUVE®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Typical antipsychotic (dopamine antagonist). Area: Psychiatry / Behavioral Health.

phase 2 Typical antipsychotic (dopamine antagonist) Dopamine D1 and D2 receptors Psychiatry / Behavioral Health Small molecule Live · refreshed every 30 min

Target snapshot

ADASUVE® (ADASUVE®) — Teva Branded Pharmaceutical Products R&D, Inc.. ADASUVE is a loxapine inhalation powder that blocks dopamine receptors in the brain to rapidly reduce agitation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ADASUVE® TARGET ADASUVE® Teva Branded Pharmaceutical Products R&D, Inc. phase 2 Typical antipsychotic (dopamine antagonist) Dopamine D1 and D2 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Typical antipsychotic (dopamine antagonist) class)

  1. Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ADASUVE® — Competitive Intelligence Brief. https://druglandscape.com/ci/adasuve. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: